Acquired rifamycin resistance: pharmacology and biology

References

• Wright A, Bai G, Barrera L et al. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000–2004. MMWR Morb. Mortal. Wkly Rep.55(11), 301–305 (2006).
   PubMedGoogle Scholar
• Dong Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of M. tuberculosis.Antimicrob. Agents Chemother.44(9), 2581–2584 (2000).
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother.41(12), 2670–2679 (1997).
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob. Agents Chemother.43(3), 568–572 (1999).
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet.40(5), 327–341 (2001).
   PubMed Web of Science ®Google Scholar
• Chan CY, Au-Yeang C, Yew WW, Hui M, Cheng AF. Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrob. Agents Chemother.45(12), 3631–3634 (2001).
   PubMedGoogle Scholar
• Chan CY, Au-Yeang C, Yew WW, Leung CC, Cheng AF. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother.48(1), 340–343 (2004).
   PubMed Web of Science ®Google Scholar
• Dickinson JM, Mitchison DA. In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens. Tubercle49(Suppl.), 70 (1968).
   PubMedGoogle Scholar
• Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother.51(11), 3781–3788 (2007).
   PubMed Web of Science ®Google Scholar
• Dickinson JM, Ellard GA, Mitchison DA. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle49(4), 351–366 (1968).
   PubMedGoogle Scholar
• Dickinson JM, Mitchison DA. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle51(1), 82–94 (1970).
   PubMedGoogle Scholar
• Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med.167(4), 603–662 (2003).
   PubMed Web of Science ®Google Scholar
• Mwandumba HC , Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst. Rev. (4), CD000970 (2001).
   PubMedGoogle Scholar
• Kwok CC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med.174, 1153–1158 (2006).
   PubMedGoogle Scholar
• Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet353(9167), 1843–1847 (1999).
   PubMed Web of Science ®Google Scholar
• Weiner M, Burman W, Vernon A et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med.167(10), 1341–1347 (2003).
   PubMed Web of Science ®Google Scholar
• Burman W, Benator D, Vernon A et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med.173(3), 350–356 (2006).
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Burman W et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis.40(10), 1481–1491 (2005).
   PubMed Web of Science ®Google Scholar
• Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000. Clin. Infect. Dis.41(1), 83–91 (2005).
   PubMed Web of Science ®Google Scholar
• Nettles RE, Mazo D, Alwood K et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin. Infect. Dis.38(5), 731–736 (2004).
   PubMedGoogle Scholar
• Lutfey M, la-Latta P, Kapur V et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am. J. Respir. Crit. Care Med.153(2), 837–840 (1996).
   PubMedGoogle Scholar
• van Crevel R, Alisjahbana B, de Lange WC et al. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia. Int. J. Tuberc. Lung Dis.6(6), 497–502 (2002).
   PubMed Web of Science ®Google Scholar
• Taylor B , Smith PJ. Does AIDS impair the absorption of antituberculosis agents? Int. J. Tuberc. Lung Dis.2(8), 670–675 (1998).
   PubMedGoogle Scholar
• Keung AC, Owens RCJ, Eller MG, Weir SJ, Nicolau DP, Nightingale CH. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a Phase I study. Antimicrob. Agents Chemother.43(5), 1230–1233 (1999).
   PubMed Web of Science ®Google Scholar
• Cheon SH, Kampmann B, Hise AG et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin. Diagn. Lab. Immunol.9(4), 901–907 (2002).
   PubMedGoogle Scholar
• Larkin R, Benjamin CD, Hsu YM, Li Q, Zukowski L, Silver RF. CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes. Infect. Immun.70(8), 4716–4720 (2002).
   PubMedGoogle Scholar
• Kampmann B, Gaora PO, Snewin VA, Gares MP, Young DB, Levin M. Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. J. Infect. Dis.182(3), 895–901 (2000).
   PubMed Web of Science ®Google Scholar
• Janulionis E, Sofer C, Schwander S et al. Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity. Infect. Immun.73(5), 2595–2601 (2005).
   PubMedGoogle Scholar
• Saliu O, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis.194, 486–492 (2006).
   PubMed Web of Science ®Google Scholar
• Hoft DF, Worku S, Kampmann B et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J. Infect. Dis.186(10), 1448–1457 (2002).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Vinhas SA, Johnson JL et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J. Infect. Dis.187, 270–278 (2003).
   PubMed Web of Science ®Google Scholar
• Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet359(9323), 2059–2064 (2002).
   PubMed Web of Science ®Google Scholar
• Tena GN, Young DB, Eley B et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus, and its relationship to T cell function. J. Infect. Dis.187(10), 1544–1551 (2003).
   PubMed Web of Science ®Google Scholar
• Kampmann B, Tena-Coki GN, Nicol M, Levin M, Eley B. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS20(7), 1011–1018 (2006).
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Hafner R, Wu JW et al. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res. Hum. Retroviruses.21(8), 689–695 (2005).
   PubMedGoogle Scholar
• Armbruster C, Junker W, Vetter N, Jaksch G. Disseminated bacille Calmette–Guerin infection in an AIDS patient 30 years after BCG vaccination. J. Infect. Dis.162(5), 1216 (1990).
   PubMed Web of Science ®Google Scholar
• Blondon H, Guez T, Paul G, Truffot-Pernot C, Sicard D. BCG adenitis 6 years after vaccination in an AIDS patient. Presse Med.20, 1091 (1991).
   PubMedGoogle Scholar
• Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am. Rev. Respir. Dis.146, 285–289 (1992).
   PubMed Web of Science ®Google Scholar
• Brill KJ, Li Q, Larkin R et al. Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms. Infect. Immun.69(3), 1755–1765 (2001).
   PubMed Web of Science ®Google Scholar
• Bermudez LE, Wu M, Young LS. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect. Immun.63(10), 4099–4104 (1995).
   PubMedGoogle Scholar
• Mitchison DA , Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis.133(3), 423–430 (1986).
   PubMed Web of Science ®Google Scholar
• Campos PE, Suarez PG, Sanchez J et al. Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerg. Infect. Dis.9(12), 1571–1578 (2003).
   PubMedGoogle Scholar
• Mac-Arthur A, Gloyd S, Perdigao P, Noya A, Sacarlal J, Kreiss J. Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. Int. J. Tuberc. Lung Dis.5(10), 894–902 (2001).
   PubMed Web of Science ®Google Scholar
• Robert J, Trystram D, Truffot-Pernot C, Jarlier V. Multidrug-resistant tuberculosis: eight years of surveillance in France. Eur. Respir. J.22(5), 833–837 (2003).
   PubMedGoogle Scholar
• Moro ML, Gori A, Errante I et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS12(9), 1095–1102 (1998).
   PubMedGoogle Scholar
• Haar CH, Cobelens FG, Kalisvaart NA, van der Have JJ, van Gerven PJ, van Soolingen D. Tuberculosis drug resistance and HIV infection, The Netherlands. Emerg. Infect. Dis.13(5), 776–778 (2007).
   PubMedGoogle Scholar
• Quy HT, Buu TN, Cobelens FG, Lan NT, Lambregts CS, Borgdorff MW. Drug resistance among smear-positive tuberculosis patients in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis.10(2), 160–166 (2006).
   PubMed Web of Science ®Google Scholar
• Espinal MA, Laserson K, Camacho M et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int. J. Tuberc. Lung Dis.5(10), 887–893 (2001).
   PubMed Web of Science ®Google Scholar
• Lambregts-van Weezenbeek CS, Jansen HM, Nagelkerke NJ, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcome. Int. J. Tuberc. Lung Dis.2(4), 288–295 (1998).
   PubMed Web of Science ®Google Scholar
• Weyer K, Levin J, van der Walt M, Brand J, Lancaster J. Determinants of multi-drug resistant tuberculosis in South Africa. S. Afr. Med. J.97(11), 1120–1128 (2007).
   PubMed Web of Science ®Google Scholar
• Wilkinson D, De Cock KM. Tuberculosis control in South Africa – time for a new paradigm? S. Afr. Med. J.86(1), 33–35 (1996).
   PubMedGoogle Scholar
• Moore D, Liechty C, Ekwaru P et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS21(6), 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J. Clin. Epidemiol.48(1), 23–40 (1995).
   PubMed Web of Science ®Google Scholar
• Ribaudo HJ, Haas DW, Tierney C et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis.42(3), 401–407 (2006).
   PubMed Web of Science ®Google Scholar
• Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin. Infect. Dis.42(3), 408–410 (2006).
   PubMed Web of Science ®Google Scholar